Austria Cannot Offer Short Timelines For Reviewing Clinical Trials Under CTIS
Executive Summary
Austria may not be part of an important monkeypox clinical trial taking place in several European Economic Area countries, but discussions on the study made the Austrian regulator realize its limitations in undertaking fast-track evaluations under the EU Clinical Trial Regulation.
You may also be interested in...
Pakistan Explains Updated Risk-Based Criteria For GCP Inspections
Pakistan’s drug regulator is hoping that improved transparency on its inspection protocols will help research entities better prepare for good clinical practice inspections.
UK MHRA Inspector Highlights Mistakes Made In Decentralized Clinical Trials
Inadequate risk assessments, participant confidentiality breaches and issues with documenting and verifying clinical trial activities have emerged as recurring themes in inspections of decentralized clinical trials by the UK medicines regulator.
UK, US & Canada Regulators Explain Why Decentralized Trials May Get A Closer Look
Decentralized clinical trials are subject to the same regulatory requirements as traditional site-based trials, but are of special interest to regulators because they represent a new way of working.